Analysts Conflicted on These Healthcare Names: NovoCure Ltd (NASDAQ: NVCR) and Bioverativ Inc (NASDAQ: BIVV)

By Carrie Williams

Analysts have been eager to weigh in on the Healthcare sector with new ratings on NovoCure Ltd (NASDAQ: NVCR) and Bioverativ Inc (NASDAQ: BIVV).

NovoCure Ltd (NASDAQ: NVCR)

Wells Fargo analyst Larry Biegelsen upgraded NovoCure Ltd (NASDAQ: NVCR) to Buy today. The company’s shares closed yesterday at $11.60.

According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 15.6% and a 72.6% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Merit Medical Systems.

NovoCure Ltd has an analyst consensus of Strong Buy, with a price target consensus of $16.

Bioverativ Inc (NASDAQ: BIVV)

Bioverativ Inc (NASDAQ: BIVV) received a Hold rating from Credit Suisse analyst Alethia Young today. The company’s shares closed yesterday at $52.50.

According to TipRanks.com, Young is a 3-star analyst with an average return of 1.2% and a 44.9% success rate. Young covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Ionis Pharmaceuticals Inc, and Alexion Pharmaceuticals.

Currently, the analyst consensus on Bioverativ Inc is Moderate Buy and the average price target is $57.14, representing an 8.8% upside.

In a report released yesterday, Cowen & Co. also reiterated a Hold rating on the stock with a $47 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.